Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Bristol-Myers

Bristol-Myers (BMY), Ono Pharmaceutical and Bayer ink a collaboration deal to evaluate the combination of Opdivo plus Stivarga for treating micro-satellite stable metastatic colorectal cancer.

Bristol-Myers, Ono, Bayer Team Up for Colorectal Cancer Study

Germany's Bayer AG  on Friday welcomed a conditional ruling by a U.S. judge calling for a retrial of the case of a couple awarded $2 billion in damages by a jury who found that its glyphosate-based weedkiller caused their cancer.

Bayer welcomes judge's call for new trial in $2 billion glyphosate case

Alexion Pharma

Canadian Solar

JinkoSolar Holding

Legg Mason

SYNNEX

P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.

6 Low Price-to-Book Value Stocks to Buy for Solid Returns

Evogene

Evogene Ltd. (NASDAQ: EVGN) is amending its collaboration with Bayer AG (OTC: BAYRY)'s crop science division to identify genome editing targets for evaluation against a broad range of corn diseases.

Evogene Tackles Corn Crop Fungal Diseases With Bayer

Shares in German chemicals company Bayer  rose 1.8% in early trade on Tuesday after a U.S. judge slashed a damages award Bayer owes a California man who blamed its Roundup weed killer for his cancer.

Bayer shares up 1.8% trade after U.S. Roundup rule

Shares in German chemicals company Bayer  rose 2.8% in early trading in Frankfurt on Tuesday after a U.S. judge slashed a damages award Bayer owes a California man who blamed its Roundup weed killer for his cancer.

Bayer shares up 2.8% in early Frankfurt trade after U.S. Roundup rule

A federal judge on Monday reduced a damages award that Bayer AG owed a man who blamed his cancer on the glyphosate-based weed killer Roundup to $25.27 million from $80 million, saying the punitive damages component was too high.

U.S. judge slashes $80 million Roundup jury verdict to $25.3 million

Elanco Animal Health Inc

Bayer and Elanco Reportedly in Early Merger Talks; Deal Worth over $6.0 Billion. Spin-Off Research, founded by Joe Cornell, has tracked and provided analysis on Spin-Offs since 1997.

Elanco Animal Health And Bayer In Early Talks To Combine Animal Health Units

Brazilian cotton producers in the state of Mato Grosso on Thursday sued Bayer AG , seeking to cancel the chemical company's patent protection for its Bollgard II RR Flex genetically modified cotton seed, according to a statement sent to Reuters.

Brazil cotton farmers sue Bayer over patent on GMO seed

Johnson & Johnson

Bayer's (BAYRY) Xarelto, in the phase III EINSTEIN-Jr study in pediatric patients, shows a similar low risk of VTE or blood clots compared to current standard anticoagulation therapy.

Bayer-J&J Announce Positive Xarelto Data in Children with VTE

The two companies are working with banks to ensure any merger would secure regulatory approval.

German pharmaceutical company Bayer seeks animal health merger with Elanco

Bayer  has approached U.S. drug firm Elanco Animal Health  to discuss a possible combination of their pet-health businesses to create an industry giant, three sources familiar with the matter told Reuters.

Exclusive: Germany's Bayer seeks animal health merger with Elanco - sources

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Bayer (BAYRY) Right Now?

A juror who was part of a panel that delivered an $80 million award against Bayer AG  after finding that its glyphosate-based weed killer Roundup caused a man's cancer has urged the presiding judge to uphold the decision.

Juror urges U.S. judge to uphold $80 million Roundup verdict against Bayer

AbbVie

GlaxoSmithKline

Eli Lilly

Merck

Novartis

Pfizer

Roche Holding AG

Sanofi

SPDR S&P Pharmaceuticals ETF

"We're working on it right now a favored nations clause where we pay the lower nation's price is, like Canada," President Donald Trump tells reporters.

Trump says administration preparing an executive order on drug prices

Activist investor, Elliott Advisors, discloses a 1.1-billion-euro ($1.3 billion) stake in Bayer (BAYRY). It forms a new committee and hires U.S.

Bayer Sets Up Special Committee to Tackle Glyphosate Lawsuits

Bayer  shares jumped on Thursday after it revealed plans aimed at resolving multi-billion dollar lawsuits linked to glyphosate, a move welcomed by activist shareholder Elliott, which has taken a sizeable stake in the chemicals company.

Bayer lifted by new plan to tackle glyphosate lawsuits, Elliott approval

Chemicals giant Bayer, under pressure from activist shareholders, said on Wednesday it has hired an external lawyer to advise its supervisory board and has set up a new committee to resolve a multi-billion dollar glyphosate litigation issue.

Bayer seeks outside advice on litigation as Elliott reveals stake

Bayer AG has asked a California judge to overrule a $2 billion verdict by jurors who found the company's glyphosate-based Roundup weed killer responsible for a couple's cancer, arguing the jury decision was not supported by evidence.

Bayer asks trial judge to reverse $2 billion Roundup jury verdict

Bayer (BAYRY) announces that it will invest 5 billion euros in developing new weedkillers amid lawsuits claiming its glyphosate-based weedkillers cause cancer.

Bayer to Invest 5 Billion Euros in Weedkiller Research

Bayer (BAYRY) announced last Friday that it is set to invest approximately 5 billion euros, or around $5.6 billion, in order to further research "additional methods to combat weeds."

Will Bayer's Investment in its Reputation Boost BAYRY Stock?

Germany's Bayer sought to repair its reputation on Friday after damage caused by U.S. litigation over claims its glyphosate pesticide causes cancer, saying it would invest 5 billion euros ($5.6 billion) in weedkiller research.

Bayer to invest $5.6 billion in weedkiller research to help reputation

Bayer said it would invest 5 billion euros ($5.6 billion) in developing new weedkillers and reducing its environmental impact by 30% by 2030, as it seeks to address the fallout from U.S. class-action litigation over glyphosate.

Bayer says to invest 5 billion euros in new weed killers

Bayer's (BAYRY) Aliqopa gets Breakthrough Thearpy designation from the FDA for the treatment of adult patients with relapsed marginal zone lymphoma, who have received at least two prior therapies.

Bayer's Aliqopa Gets Breakthrough Therapy Status by FDA

Alnylam Pharmaceuticals

BioMarin Pharmaceutical

BioMarin (BMRN) announces significant reduction in annual bleed rate in phase III study evaluating gene therapy, valoctocogene roxaparvovec, in hemophilia A patients. However, investors are skeptical.

BioMarin Announces Data on Hemophilia Candidate, Shares Fall

News for Bayer AG Stock (BAYRY)